Know Cancer

forgot password

A Phase Ib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens.

Phase 1
18 Years
Open (Enrolling)
Non Small Cell Lung Cancer

Thank you

Trial Information

A Phase Ib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens.

The purpose of this study is to find the highest dose of a new drug, selumetinib, given in
combination with standard chemotherapies, that can be tolerated without causing very severe
side effects. This is done by starting at a dose lower than the one that does not cause side
effects in animals. Participants are given selumetinib and are watched very closely to see
what side effects they have and to make sure the side effects are not severe. If the side
effects are not severe, then more potential participants are asked to join this study and
are given a higher dose of selumetinib. Participants joining this study later on will take
selumetinib at higher doses, take doses twice daily or take for more days in a 21 day period
than participants who join earlier. This will continue until a dose is found that causes
severe but temporary side effects. Doses higher than that will not be given.

Inclusion Criteria:

- Patients must have histologically and/or cytologically confirmed non-small cell lung
cancer that is metastatic or unresectable and for which standard curative measures do
not exist.

- All patients must have a formalin fixed paraffin embedded tissue block (from primary
or metastatic tumour) available for correlative studies and must have provided
informed consent for the release of the block as well as for blood samples for
correlative studies.

- Patients planned for the pemetrexed single agent cohort, as well as those accrued to
the RP2D expansion cohorts must have a documented KRAS mutation, as well as at least
one site of disease which is unidimensionally measurable as follows:

- Measurable disease defined as at least one target lesion that has not been irradiated
and can be accurately measured in at least one dimension by RECIST 1.1 criteria.

- Chest X-ray ≥ 20 mm

- CT/MRI scan (with slice thickness of < 5 mm) ≥ 10 mm --> longest diameter

- Physical exam (using calipers) ≥ 10 mm

- Lymph nodes by CT scan ≥ 15 mm --> measured in short axis

- Presence of clinically and/or radiologically documented disease (marker positive only
patients are not eligible).

All radiology studies must be performed within 28 days prior to registration (within 35
days if negative).

- Age > 18 years.

- ECOG performance status 0 or 1

- Patients must have a life expectancy of at least 12 weeks.

Previous Therapy


Previous major surgery is permitted provided it has been at least 14 days prior to patient
registration and that wound healing has occurred.


Prior external beam radiation is permitted provided a minimum of 4 weeks has elapsed
between the last dose and enrollment to the trial.

Chemotherapy and systemic therapy:

Patients may not have received prior MEK inhibitors or any other tyrosine kinase inhibitor
(including EGFR inhibitors of any kind).

Prior adjuvant chemotherapy or combined chemoradiotherapy with curative intent is
permissible provided completed at least one year prior to enrollment.

No prior cytotoxic chemotherapy for advanced / metastatic disease is permissible, UNLESS
patient is to be enrolled in the pemetrexed single agent cohort. Patients for this cohort
must be candidates for single agent pemetrexed, have received no prior pemetrexed and have
had no more than one prior chemotherapy regimen for advanced or metastatic disease.

Laboratory Requirements (must be done within 7 days prior to registration)


Neutrophils ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L


Creatinine Clearance* ≥ 50 ml/min (calculated by Cockcroft and Gault equation) Total
bilirubin ≤ 1.5 x ULN AST and ALT ≤ 2.5 x ULN (≤ 5x ULN in the presence of liver

- Patient consent must be appropriately obtained in accordance with applicable local
and regulatory requirements. Each patient must sign a consent form prior to
enrollment in the trial to document their willingness to participate.Patients who
cannot give informed consent (i.e. mentally incompetent patients, or those physically
incapacitated such as comatose patients) are not to be recruited into the study.
Patients competent but physically unable to sign the consent form may have the
document signed by their nearest relative or legal guardian. Each patient will be
provided with a full explanation of the study before consent is requested.

- Patients must be accessible for treatment and follow-up. Patients registered on this
trial must be treated and followed at the participating centre. This implies there
must be reasonable geographical limits (for example: 1 ½ hour's driving distance)
placed on patients being considered for this trial. Investigators must assure
themselves the patients registered on this trial will be available for complete
documentation of the treatment, adverse events, and follow-up.

- Treatment is to begin within 2 working days of patient registration.

Exclusion Criteria:

- Patients with a history of other untreated malignancies or malignancies which
required therapy within the past 2 years.

- Patients with documented brain metastasis or carcinomatous meningitis, treated or

- Patients with significant cardiac disease, including:

- any factors that increase the risk of QTc prolongation or risk of arrhythmic events
(e.g. heart failure, hypokalaemia, congenital long QT syndrome, family history of
long QT syndrome or unexplained sudden death under 40 years of age) or mean resting
corrected QT interval (QTc) > 470 msec

- uncontrolled hypertension (BP ≥ 150/95 mmHg despite medical therapy)

- acute coronary syndrome within 6 months prior to starting treatment

- angina Canadian Cardiovascular Society Grade II-IV (despite medical therapy)

- symptomatic heart failure (NYHA II-IV)

- prior or current cardiomyopathy

- atrial fibrillation with a ventricular rate > 100bpm at rest

- severe valvular heart disease

- Other patients with cardiac disease, who do not meet the exclusion criteria above,
must have a baseline LVEF ≥ 55%.

- Patients who have neuropathy > grade 1 or other conditions precluding treatment with
the standard chemotherapy regimen planned.

- Patients who have significant gastrointestinal disease and who are unable to swallow

- Patients on potent inhibitors or inducers of CYP3A4/5, CYP2C19 and CYP1A2 (must have
discontinued within 2 weeks prior to registration (3 weeks for St. John's Wort).
Patients who do not agree to avoid the ingestion of large amounts of grapefruit and
Seville oranges (and other products containing these fruits, e.g. grapefruit juice or
marmalade) and not take vitamin E supplements or multivitamin supplements which
provide a total daily dose in excess of 100% of the recommended daily allowance for
vitamin E.

Patients who require oral anticoagulants (coumadin) are eligible provided there is
increased vigilance with respect to monitor INR, upon initiation of dosing with
selumetinib. If medically appropriate and treatment available, the investigator should
consider switching these patients to LMW heparin.

- Patients with current or past history of central serous retinopathy or retinal vein
occlusion, high intraocular pressure or uncontrolled glaucoma (irrespective of IOP).

- Pregnant or lactating women. Women of childbearing potential must have a urine
pregnancy test proven negative within 7 days prior to registration. Men and women of
child-bearing potential must agree to use adequate contraception.

- Patients who do not agree to avoid excessive sun exposure and use adequate sunscreen

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum dose tolerability of Selumetinib in patients

Outcome Description:

Determination of the maximum administered dose and the recommended phase II dose

Outcome Time Frame:

24 months

Safety Issue:


Principal Investigator

Garth Nicholas

Investigator Role:

Study Chair

Investigator Affiliation:

Ottawa Health Research Institute - General Division


Canada: Health Canada

Study ID:




Start Date:

January 2013

Completion Date:

July 2015

Related Keywords:

  • Non Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms